Related Experiment Video
Updated: Jul 9, 2025
Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
Evaluation of the Coenzyme Q10 and Some Biochemical Parameters in Patients with Ischemic Heart Disease
O M Ayob Alsaiegh1, A Lateef Husein1, Mohammad M Harith2
1Department of Biochemistry, College of Medicine University of Tikrit, Tikrit, Iraq.
Insights
Low Coenzyme Q10 (CoQ10) levels are linked to ischemic heart disease (IHD). This study found lower CoQ10 in IHD patients, suggesting its potential role in cardiovascular disease management.
Area of Science:
- Cardiology
- Biochemistry
- Medical Diagnostics
Background:
- Ischemic heart disease (IHD) is a major global cause of mortality.
- Cardiac biomarkers are crucial for diagnosing and managing cardiovascular diseases.
- Coenzyme Q10 (CoQ10) is investigated for its potential role in cardiovascular health due to its role in cellular bioenergetics.
Purpose of the Study:
- To evaluate the role of Coenzyme Q10 (CoQ10) and other biochemical markers in patients with ischemic heart disease (IHD).
- To assess the relationship between CoQ10 levels and common cardiac markers in IHD patients.
Main Methods:
- A case-control study involving 90 participants (60 IHD patients, 30 healthy controls) in Iraq.
- Measurement of serum levels of Coenzyme Q10 (CoQ10), C-reactive protein (CRP), creatine phosphokinase (CPK), troponin, and lactate dehydrogenase (LDH).
- Analysis of lipid profiles and correlation of CoQ10 with age, BMI, and cardiac markers.
Main Results:
- Patients with IHD exhibited significantly lower serum CoQ10 levels compared to controls.
- Elevated levels of serum lactate dehydrogenase (LDH), CRP, CPK, and troponin were observed in the IHD group.
- A significant negative correlation was found between CoQ10 levels and age, LDH, CRP, and troponin.
Conclusions:
- Serum Coenzyme Q10 (CoQ10) levels are significantly lower in patients with ischemic heart disease (IHD).
- CoQ10 may play a role in the pathogenesis or progression of IHD.
- Further research into CoQ10 supplementation for IHD prevention and treatment is warranted.
Abstract:
Ischemic heart disease (IHD) is a common diagnosis and a leading cause of death in both males and females. It accounts for 30% of deaths worldwide, including 40% in high-income countries and approximately 28% in developing nations. Several cardiac markers have been used to diagnose and manage cardiovascular diseases. The Coenzyme Q10 (CoQ10) plays a potential role in the prevention and treatment of cardiovascular diseases by improving cellular bioenergetics. This study aimed to evaluate the role of CoQ10 and other biochemical parameters in IHD (angina pectoris and myocardial infarction). A case-control study was conducted at the Intensive Care Unit of Ibn-Sina Teaching Hospital and Al-Salam General Hospital in Nineveh Province, Iraq, for two months, from April 1 to June 1, 2022. It included 90 adult participants divided into case and control groups. The case group included 60 patients admitted to the Intensive Care Unit and diagnosed with IHD (myocardial infarction or angina pectoris), and the control group included 30 healthy participants matched in age and gender with the case group. Subsequent assay of C-reactive protein (CRP), creatine phosphokinase (CPK), troponin level, and serum CoQ10. In this study, 81.7% of patients in the case group were diagnosed with myocardial infarction. Means of serum lactate dehydrogenase (LDH), CRP, CPK, and troponin were significantly higher, while those of CoQ10 were significantly lower in the case group, compared to the controls. Statistically, a significant moderate negative correlation was detected between CoQ10 level and age. Moreover, significant weak correlations were observed between CoQ10 level and all serum LDH, CRP, and troponin levels. Patients with IHDs had considerably low serum levels of CoQ10, compared to the control group. The highest mean value of lipid profile, except for triglyceride, was observed in patients with IHD, compared to the control group. This explains the role that cholesterol compounds play in the progression of IHD. No significant correlations were found between CoQ10 with body mass index and CPK. The CoQ10 had a negative correlation with age, serum LDH, CRP, and troponin.
